Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-SEEK trial of urinary kallidinogenase for acute ischemic stroke with type 2 diabetes mellitus
ChiCTR2300076356Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Human urinary kallidinogenase in ischemic stroke (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Proportion of patients with modified Rankin Scale score 0-2 at 90 ± 7 days after stroke. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Human urinary kallidinogenase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300076356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076356.